Genzyme Genetics, Cambridge, Mass, has signed a sublicense agreement with DxS Ltd, Manchester, UK in which it will grant DxS worldwide rights with the exception of North America and Hong Kong for diagnostic testing of epidermal growth factor receptor mutations in non-small cell lung cancer.
Read More
The FDA has approved Thermo Fisher’s Oncomine Dx Express Test on the Genexus Dx Integrated Sequencer as a companion diagnostic for ZEGFROVY.
Read More
Vizgen and Hamamatsu Photonics have partnered to integrate advanced multiplex imaging and assay technologies, streamlining workflows.
Read More
Labcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.
Read More
Roche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read More